INTRODUCTION

Imatinib (GLEEVEC ® , GLIVEC
 , imatinib mesylate, formerly STI571; Fig. 6 ) has demonstrated efficacy in cancer treatment by virtue of its ability to potently and selectively inhibit the BCR-ABL tyrosine kinase as well as the platelet derived growth factor receptors α− and β−PDGFRs and KIT receptor tyrosine kinases (Fabbro et al., 2002 ) .
The pathogenesis of chronic myelogenous leukemia (CML) has been attributed to expression of the BCR-ABL fusion oncogene formed by an aberrant chromosomal translocation that generates the Philadelphia chromosome (Deininger et al., 2003) . Gainof-function mutations of KIT and PDGFRs have been associated with gastrointestinal stromal tumors (GIST) (Hirota et al., 1998) (Rubin et al., 2001 ) (Dagher et al., 2002) .
Imatinib is also indicated for treatment of metastatic and unresectable malignant GIST (Demetri et al., 2002) . Imatinib is now the first line therapy for all phases of CML and GIST (O'Brien et al., 2003a) .
Expansion of the clinical applications of imatinib is anticipated. Dysregulated PDGFR kinase activity has been linked to a variety of cancers including glioblastoma, dermatofibrosarcoma protuberans (DFSP), idiopathic hypereosinophilic syndrome (HES) as well as other myeloproliferative diseases (Tuveson and Fletcher, 2001 ) (le Coutre et al., 2004) . In addition, imatinib has also been shown, in animal models, to enhance the antitumor effects of chemotherapeutic agents due to inhibition of PDGFRβ  (Pietras et al., 2002) and therefore may have potential efficacy as an adjuvant therapy.
The purpose of this study was to investigate the disposition and biotransformation of imatinib mesylate in healthy volunteers as part of the clinical development of the This article has not been copyedited and formatted. The final version may differ from this version. While previous studies have reported on pharmacokinetic and pharmacodynamic properties as well as the overall tolerability and safety of imatinib in the plasma of CML patients (Peng et al., 2004b ) (Schmidli et al., 2005) and healthy volunteers (Nikolova et al., 2004) , data presented here include the complete characterization of the absorption, distribution, metabolism and excretion (ADME) of a single oral dose of 14 C-imatinib administration to healthy volunteers. Solvents and reagents, all of analytical grade, were purchased from commercial manufacturers.
MATERIALS AND METHODS
Reference
This article has not been copyedited and formatted. The final version may differ from this version. A blank urine sample (250 mL) was collected the day before dose administration and urine and feces were collected completely after dose administration. The subjects were confined to the clinical premises during the sampling period. They had access only to toilets specially equipped for lossless sample collection.
Sample storage and shipment conditions. After sample collection, blood, plasma, urine and feces samples were kept refrigerated at 4-8ºC. Later on, the samples were stored frozen at ≤ -18ºC until and after analysis in the analytical laboratories. Stability of imatinib and its metabolites was ascertained under these conditions (Bakhtiar et al., 2002) . Samples were shipped to other analytical laboratories under dry ice.
Analysis of unchanged imatinib and its main metabolite CGP74588. Concentrations of imatinib and its major metabolite (CGP74588) in all plasma samples of each individual subject were quantified by a validated specific assay based on liquidchromatography-mass spectrometry (Bakhtiar et al., 2002) .
Radioactivity analysis of blood, plasma, urine and feces samples. Determination of 14 C radioactivity in blood, plasma and urine samples (3 replicates per time point) was performed using a Tri-Carb 2000 CA or TR 2500 liquid scintillation counter (LSC) (Packard Instruments, Meridian, CT, USA). Feces samples (4 replicates) were combusted in a Packard A307 oxidizer (Packard) and the 14 CO 2 produced was trapped into the alkaline scintillation cocktail (Carbo-Sorb ® ; Packard) and radioactivity was measured by means of LSC. Urine and plasma samples were measured directly after addition of LSC cocktail using standard counting procedures and quench correction was performed by an external standard method (Botta et al., 1985) . Radioactivity determination in pooled feces homogenates as well as residual pellets from extractions for metabolism investigations This article has not been copyedited and formatted. The final version may differ from this version. and 1 were injected in this order onto the HPLC column, followed by the start of the gradient elution. Collection of the solvent effluent during the loading process of the dissolutions followed by measurement of radioactivity and re-analysis of the effluent showed a loss of radioactivity of about 23% of the injected radioactivity. The proportion of non-retained components (imatinib, its major metabolite CGP74588 and the minor structurally metabolites) was the same as that retained on the HPLC column.
HPLC Instrumentation for metabolite pattern analysis (radio-HPLC)
HPLC Method 1 (used for analysis of plasma and urine) The chromatography conditions were identical for HPLC methods 1 and 2.
Evaluation of HPLC data. Plasma, urine or feces extract samples were injected onto the HPLC system and fractions were collected on Deepwell LumaPlates TM -96 (fraction volume: 0.16 mL; 12 sec/fraction). For each matrix, the recovery from the HPLC column was determined by collection of the total eluent into one flask. An aliquot of the eluent was taken for 14 C measurement by LSC. The amounts of metabolites or parent drug in plasma or excreta were derived from the radio-chromatograms (metabolite patterns) by dividing the radioactivity eluting from the HPLC column (equal to radioactivity in original sample minus losses during sample preparation and chromatography) in proportion to the relative peak areas. Parent drug or metabolites were expressed as concentrations (µmol/L) in plasma or as percent of dose in excreta. These values are to be considered as semi-quantitative only, as opposed to those determined by the validated quantitative LC-MS assay (Bakhtiar et al., 2002) . (Kretz et al., 2004) .
RESULTS
Pharmacokinetics of imatinib, CGP74588 and total radioactivity. Following a single oral dose of nominal 239 mg [ 14 C]imatinib mesylate, the mean maximum plasma levels of radioactivity, imatinib and its pharmacologically active N-desmethyl metabolite CGP74588 were reached rapidly between 1 and 2 hours post-dose, suggesting rapid absorption (Fig. 1) . The total radioactivity at C max represented mainly unchanged drug (mean. 92%, range: 86%-99%) and CGP74588 (mean: 12%, range: 9%-14%). The key pharmacokinetic parameters are summarized in Table 1 . Inter-individual differences in plasma concentrations and in pharmacokinetic parameters were small. Imatinib accounted for 65% of total radioactivity AUC 0-24h in plasma and the metabolite CGP74588 accounted for 9%. The remaining proportion was due to a number of minor and trace metabolites of imatinib, as detected by off-line microplate solid-scintillation counting (TopCount™) following HPLC separation. Many of them could be characterized at least partially by LC-MS.
About 23% of the radioactivity in blood was calculated to have been taken up into red blood cells. Thus imatinib and its metabolites are present largely in the plasma (77%). For comparison, the fraction of unchanged imatinib in plasma of healthy volunteers in vitro was 74% (Kretz et al., 2004) .
This article has not been copyedited and formatted. The final version may differ from this version. Excretion and mass balance in urine and feces. Radioactivity was excreted slowly in all four subjects. After 2 days only about a quarter of the dose was recovered.
Radiolabeled material was excreted largely with the feces (range, 60.6% -71.3%; over 7 days). A minor proportion was excreted in urine with a small inter-individual variability (range, 12.2%-15.6%, up to 7 days). Correspondingly, the mean total recovery in excreta over 7 days was 80.2% (range 72.9% -83.6%). By 11 days mean total recovery in excreta was 81.1% (range 74.2% -84.7%). The results are summarized in Table 2 .
Metabolite characterization by LC-MS. Metabolite structures were characterized by LC-MS (data in Table 3 ) and, where possible, confirmed by comparison of mass spectra and retention times with authentic reference compounds (metabolites AFN911, CGP74588, CGP72383, APG049, CGP71422 and APG050). The proposed partial or complete structures are given in Table 4 .
The electrospray mass spectrum of imatinib taken at 80 V up-front collision offset ( The metabolites of imatinib underwent predominantly fragmentations analogous to those of the parent drug, allowing to localize metabolic changes in the substructures of the parent drug molecule reflected by its charged or neutral mass spectral fragments. The proposed metabolite structures were further supported by exact mass measurements of their M+H + ions and by hydrogen-deuterium exchange data (Table 3 ). The mass spectra of some of the metabolites showed special features that provided additional structural information as described below.
Metabolites APG050 and APG049 were identified as the 3-oxopiperazine derivatives of imatinib and CGP74588, respectively, by comparison with the corresponding reference compounds. Their mass spectra showed a characteristic water adduct of Fragment E (Table 3) , confirmed by exact mass measurement, with an intensity higher than that of Fragment E. M23.7 is proposed to be a glucuronide of APG050 as it showed the same characteristic intensity ratio of Fragment E + H 2 O / Fragment E >1. In contrast to APG050, the mass spectrum of the closely related isomeric metabolite M29.6 showed no Metabolism. The metabolite patterns in plasma (Fig. 3) , urine ( structures of which could be partially characterized by LC-MS (eight of them in Table 4 ).
They individually ranged between 0.2% and 4% of total 14 C-AUC 0-24h .
In the excreta, about 5% and 1.8%, and 23% and 11% of the dose accounted for imatinib and its N-desmethyl metabolite CGP74588, in 0-72 h urine and 0-168 h feces, respectively. Metabolites in urine and feces were identified by radio-HPLC combined with micro-plate solid-scintillation counting and structurally characterized by LC-MS as well as by comparison with authentic reference compounds. A representative metabolite pattern in a 0-72 h pool of urine is shown in Fig. 4 and a representative metabolite pattern in a 0-168 h pool of feces is shown in Fig. 5 . to four healthy male subjects under fasting conditions were well tolerated, without any serious adverse event or discontinuation due to an adverse event.
Absorption. The gastro-intestinal absorption of imatinib, under fasting conditions, was rapid, as concluded from the early C max values of radioactivity, of imatinib, and of the main metabolite CGP74588, typically at 1.5 hours post-dose. The extent of absorption could not be assessed in this study. However, in a previous study, the absolute oral bioavailability was determined as >97% (Peng et al., 2004a) , indicating complete absorption.
Pharmacokinetics. The mean plasma half-life of imatinib was 13.5 hours, confirming previously published data (13.9 ± 5.0 h) (Peng et al., 2004a imatinib and/or metabolites) decreased in plasma in a multi-exponential manner with a terminal half-life longer than two days. Thus, the terminal half-life of plasma radioactivity suggests some accumulation of metabolites. However, this will occur at low concentration levels and will be due to several minor metabolites, not to any single major metabolite. The pharmacokinetics of unchanged imatinib in repeated dose studies, did not change significantly and steady-state was reached in about 1 week (Peng et al 2004b) .
The accumulation factor was 1.5 to 3.0, as predicted from single dose pharmacokinetics.
Inter-individual differences in pharmacokinetics and metabolism were low. Excretion. In the observation period of 7 days, the total recovery of radioactivity in feces and urine was incomplete (mean 80.2%). Individual recoveries ranged from 72.9% to 83.6%. Otherwise, the inter-individual pharmacokinetic differences were small. Beyond the planned sample collection period of 7 days, additional feces samples were collected from three subjects from day 9 to 11, to follow the continuing excretion process. An apparent terminal elimination half-life of radioactivity in feces was estimated to approximately 3 weeks. The radioactivity was excreted largely with the feces (67.8% of dose in 11 days). A minor dose proportion was excreted in urine (13.2% in 7 days).
Imatinib was the main fecal component (23% of dose). The major proportion of fecal imatinib (about 16% of dose) was recovered in the late excretion phase. This amount of imatinib in feces could not represent non-absorbed drug since absorption and absolute oral bioavailability of imatinib were shown to be nearly complete (Peng et al., 2004a) .
The substantial fecal recovery of imatinib may be related either (i) to biliary excretion of imatinib, and/or (ii) to unstable metabolites which were reconverted back to imatinib in the gut, e.g. N-oxides and/or glucuronides, and/or (iii) to imatinib-related components secreted via the gastro-intestinal walls by-passing the biliary route. There is evidence or strong indications for all of these processes: Ramalingam and coworkers (Ramalingam et al., 2004) reported that a patient receiving daily oral doses of 300 mg imatinib excreted 17.7% and 2.1% of the dose as unchanged imatinib and CGP74588, respectively, in 0-24- Table 4 .
FIG. 4: Metabolite pattern in urine collected between 0 and 72 hours after dosing.
Urine from four subjects was pooled and centrifuged prior to HPLC analysis (Method 1).
Chemical structures of metabolites are listed in Table 4 .
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